Therapeutic potential of kava in the treatment of anxiety disorders

CNS Drugs

Volumn 16, Issue 11, 2002, Pages 731-743

  Singh, Yadhu N ^a   Singh, Nirbhay N ^b  

^a SOUTH DAKOTA STATE UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALPRAZOLAM; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ASCORBIC ACID; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CHLORDIAZEPOXIDE; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; HALAZEPAM; HYPERICUM PERFORATUM EXTRACT; ICOSANOID; KAVA; KAVALACTONE; LACTONE DERIVATIVE; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN; OXAZEPAM; PRAZEPAM; SEROTONIN UPTAKE INHIBITOR; THROMBOXANE A2; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALERIAN; VENLAFAXINE; VITAMIN B GROUP;

ABDOMINAL CRAMP; AGGRESSION; ANXIETY DISORDER; APPETITE DISORDER; ATAXIA; BEHAVIOR DISORDER; COGNITIVE DEFECT; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DROWSINESS; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HEADACHE; HEART PALPITATION; HUMAN; HYPERACTIVITY; HYPERTHERMIA; HYPOTENSION; INSOMNIA; IRRITABILITY; LIGAND BINDING; LIVER TOXICITY; MENOPAUSE; MOOD DISORDER; NAUSEA; NEUROTRANSMITTER RELEASE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; TASTE DISORDER; TINNITUS; TREMOR; VERTIGO; VISUAL IMPAIRMENT; VOMITING; WITHDRAWAL SYNDROME;

EID: 0036034312     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200216110-00002     Document Type: Review

References (116)

1. Rosenbaum JF, Gelenberg AJ. Anxiety. In: Gelenberg AJ, Bassuk EL, Schoonover SC, editors. The Practitioner's Guide to Psychoactive Drugs. New York: Plenum, 1991: 179-218
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th Ed. Washington, DC: American Psychiatric Association, 1994
3. McGlynn, FD. Simple phobia. In: Hersen M, Ammerman RT, editors. Handbook of Prescriptive Treatments for Adults. New York: Plenum, 1994: 179-96
4. Borkovec TD, Mathews A. Treatment of nonphobic anxiety disorders: A comparison of nondirective, cognitive and coping desensitization therapy. J Consult Clin Psychol 1988; 56: 877-84
5. Janicak PG, Davis JM, Preskoin SH, et al. Principles and Practice of Psychopharmacology. Philadelphia (PA): Lippincott, Williams and Wilkins, 1991
6. Barrett CM, Rapaport MH. Anxiety disorders. Psychiatr Clin North Am Annu Drug Ther 2000; 8: 181-206
7. Skaer TL, Robison LM, Sclar DA, et al. Anxiety disorders in the USA, 1990-1997: Trend in complaint, diagnosis, use of pharmacotherapy and diagnosis of comorbid depression. Clin Drug Invest 2000; 20: 237-44
8. Bond, AJ. Drug-induced behavioural disinhibition: Incidence, mechanisms, and therapeutic implications. CNS Drugs 1998; 9: 41-57
9. Van Der Bijl P, Roelofse JA. Disinhibitory reactions to benzodiazepines: A review. J Oral Maxillofac Surg 1991; 49: 519-23
10. Downing RW, Rickels K. Hostility conflict and the effect of chlordiazepoxide on change in hostility level. Compr Psychiatry 1981; 22: 362-7
11. Uhlenhuth EH, DeWit H, Balter MB, et al. Risks and benefits of long-term benzodiazepine use. J Clin Psychopharmacol 1988; 8: 161-7
12. Fraser AD. Use and abuse of the benzodiazepines. Ther Drug Monit 1998; 20: 481-9
13. Ashton H. Benzodiazepine withdrawal: Outcome in 50 patients. Br J Addict 1987; 82: 665-71
14. LaValle JB, Krinsky DL, Hawkins EB, et al. Natural Therapeutics Guide. Hudson (OH) and Cincinnati (OH): Lexi-Comp, Inc. and Natural Health Resources, 2000-2001: 342-5
15. Brevoort P. The booming U.S. botanical market: A new overview. HerbalGram 1998; 44: 33-48
16. Singh YN. Kava: An overview. J Ethnopharmacol 1992; 37: 13-45
17. Lebot V, Merlin M, Lindstrom L. Kava: the Pacific drug. New Haven (CT): Yale University Press, 1992
18. Singh YN, Blumenthal M. Kava: An overview. HerbalGram 1997; 39: 33-57
19. Klein S, Rister RS, translators. The complete German Commission E monographs. In: Blumenthal M, Busse WR, Goldberg A, et al., editors. Therapeutic Guide to Herbal Medicines. Austin (TX): American Botanical Council, 1998
20. Leung A, Foster S. Encyclopedia of Common Natural Ingredients Used in Foods, Drugs, and Cosmetics. 2nd Ed. New York: John Wiley and Sons, 1996
21. Pizzorno J, Murray M, editors. Textbook of Natural Medicine. Vol. 1. New York: Churchill Livingstone, 1999
22. Keledjian J, Duffield PH, Jamieson DD, et al. Uptake into mouse brain of four compounds present in the psychoactive beverage kava. J Pharm Sci 1988; 77 (12): 1003-6
23. Emser W, Bartylla K. Improvement in quality of sleep: Effect of kava extract WS 1490 on the sleep patterns in healthy people. TW Neurologie Psychiatrie 1991; 5: 636-42
24. Gleitz J, Gottner N, Ameri A, et al. Kavain inhibits non-stereospecifically veratridine-activated Na+-channels. Planta Med 1996; 62: 580-1
25. Brüggemann VF, Meyer H. Studies on the analgesic efficacy of the kava constituents dihydrokavain (DHK) and dihydromethysticin (DHM). Arzneimittel Forschung 1963; 13: 407-9
26. Hänsel R. Characterization and physiological activity of some kava constituents. Pacific Sci 1968; 22: 293-313
27. Jamieson DD, Duffield PH. The antinociceptive actions of kava components in mice. Clin Exp Pharmacol Physiol 1990; 17: 495-508
28. Kinzler E, Krömer J, Lehmann E. Effect of a special kava extract in patients with anxiety-, tension-, and excitation states of non-psychotic genesis: Double blind study with placebos over 4 weeks. Arzneimittel Forschung 1991; 41: 584-8
29. Lehmann E, Kinzler E, Friedemann J. Efficacy of a special kava extract (Piper methysticum) in patients with states of anxiety, tension and excitedness of non-mental origin: A double-blind placebo-controlled study of four weeks treatment. Phytomedicine 1996; III (2): 113-9
30. Singh NN, Ellis CR, Singh YN, et al. A double blind, placebocontrolled study of the effects of kava (Kavatrol) on daily stress and anxiety in adults. Altern Ther Health Med 1998; 4: 98-9
31. Pittler M, Ernst E. Efficacy of kava extract for treating anxiety: Systematic review and meta-analysis. J Clin Psychopharmacol 2000; 20 (1): 84-9
32. Pittler M, Ernst E. Kava extract for treating anxiety. The Cochrane Database of Systematic Reviews. Available in the Cochrane Library [database on disk and CD-ROM]. Updated quarterly. The Cochrane Collaboration; issue 4. Oxford: Oxford Update Software, 2001
33. Meyer HJ. Pharmacology of kava. In: Efron DM, Holmstedt B, Kline NS, editors. Ethnopharmacologic Search for Psychoactive Drugs. New York: Raven Press, 1979: 133-40
34. Seitz U, Ameri A, Pelzer H, et al. Relaxation of evoked contractile activity of isolated guinea-pig ileum by (±)-kavain. Planta Med 1997; 63: 303-6
35. Martin HB, Stofer WB, Eichinger MR. Kavain inhibits murine airway smooth muscle contraction. Planta Med 2000; 66 (7): 601-6
36. Klohs MW, Keller F, Williams E, et al. A chemical and pharmacological investigation of Piper methysticum Forst. J Med Pharm Chem 1959; 1: 95-9
37. Gleitz J, Friese J, Beile A, et al. Anticonvulsive action of (±)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. Eur J Pharmacol 1996; 315: 89-97
38. Gleitz J, Beile A, Wilkens P, et al. Antithrombotic action of the kava pyrone (+)-kavain prepared from Piper methysticum on human platelets. Planta Med 1997; 63: 27-30
39. Holm E, Staedt U, Hepp J, et al. Untersuchungen zum wirkungsprofil von D,L-kavain. Arzneimittel Forschung 1991; 41 (7): 673-83
40. Wheatley D. Kava and valerian in the treatment of stressinduced insomnia. Phytother Res 2001; 15 (6): 549-51
41. Singh YN. Effects of kava on neuromuscular transmission and muscle contractility. J Ethnopharmacol 1983; 7 (3): 267-76
42. Locher CP, Burch MT, Mower HF, et al. Anti-microbial activity and anti-complement activity of extracts obtained from selected Hawaiian medicinal plants. J Ethnopharmacol 1995; 49: 23-32
43. Backhauss C, Krieglstein J. Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. Eur J Pharmacol 1992; 215: 265-9
44. Backhauss C, Krieglstein J. Neuroprotective activity of kava extract (Piper methysticum) and its methysticin constituents in vivo and in vitro. In: Krieglstein J, Oberpichler-Schwenk H, editors. Pharmacology of Cerebral Ischemia. Stuttgart: Wissenschftliche Verlagsgellschaft mBH, 1992: 501-7
45. Gleitz J, Tosch C, Beile A, et al. The protective action of tetrodotoxin and (±)-kavain on anaerobic glycolysis, ATP content and intracellular Na+ and Ca2+ of anoxic brain vesicles. Neuropharmacology 1996; 35 (12): 1743-52
46. Warnecke G, Pfaender H, Gerster G, et al. Wirksamkeit von kawa-kawa extrakt beim klimakterischen syndrom. Z Phytother 1990; 11: 81-6
47. Warnecke G. Psychosomatische dysfunktionen im weiblichen klimakterium: Klinische wirksamkeit und verträglichkeit von kava-extrakt WS 1490. Fortschr Med 1991; 109: 119-22
48. Garner LF, Klinger JD. Some visual effects caused by the beverage kava. J Ethnopharmacol 1985; 13: 307-11
49. Ferger B, Boonen G, Häberlein H, et al. In vivo microdialysis study of (±)-kavain on veratridine-induced glutamate release. Eur J Pharmacol 1998; 347: 211-4
50. Schirrmacher K, Büsselberg D, Langosch JM, et al. Effects of (±)-kavain on voltage-activated inward currents of dorsal rhizome ganglion cells from neonatal rats. Eur Neuropsychopharmacology 1999; 9: 171-6
51. Seitz U, Schüle A, Gleitz J. [3H]-monoamine uptake inhibition properties of kava pyrones. Planta Med 1997; 63: 548-9
52. Uebelhack R, Franke L, Schewe HJ. Inhibition of platelet MAO-B by kava pyrone-enriched extract from Piper methysticum Forster (kava-kava). Pharmacopsychiatry 1998; 31: 187-92
53. Gleitz J, Beile A, Peters T. Kava inhibits veratridine-activated voltage-dependent Na+ channels in synaptosomes prepared from rat cerebral cortex. Neuropharmacology 1995; 34 (9): 1133-8
54. Magura EI, Kopanitsa MV, Gleitz J, et al. Kava extract ingredients, (±)-kavain inhibit voltage-operated Na+-channels in rat CA1 hippocampal neurons. Neuroscience 1997; 81 (2): 345-51
55. Friese J, Gleitz J. Kavain, dihydrokavain and dihydromethysticin non-competitively inhibit the specific binding of [3H]-batrachotoxinin-A 20-α-benzoate to receptor site 2 of voltage-gated Na+ channels. Planta Med 1998; 64: 458-9
56. Walden J, von Weggerer J, Winter U, et al. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 1997; 21 (4): 697-706
57. Boonen G, Ferger B, Kuschinsky K, et al. In vivo effects of the kavapyrones (+)-dihydromethysticin and (±)-kavain on dopamine, 3,4-dihydroxyphenylacetic acid, serotonin and hydroxyindoleacetic acid levels in striatal and cortical brain regions. Planta Med 1998; 64: 507-10
58. Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 1998; 27 (7): 1105-20
59. Davies L, Drew C, Duffield P. Kavapyrones and resin: Studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol 1992; 71: 120-6
60. Boonen G, Häberlein H. Influence of genuine kavapyrone enantiomers on the GABAA binding site. Planta Med 1998; 64: 504-6
61. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology 1994; 116: 469-74
62. Schwartz-Bloom RD, Cook TA, Yu X. Inhibition of GABA-gated chloride channels in brain by the arachidonic acid metabolite thromboxane A2. Neuropharmacology 1996; 35 (9-10): 1347-53
63. Sanders SK, Shekhar A. Regulation of anxiety by GABAA receptors in the rat amygdala. Pharmacol Biochem Behav 1995 Dec; 52 (4): 701-6
64. Davis M, Rainnie D, Cassell M. Neurotransmission in the rat amygdala related to fear and anxiety. Trends Neurosci 1994; 17: 208-14
65. Aston-Jones G, Rajkowski J, Kubiak P, et al. Locus coeruleus neurons in monkey are selectively activated by attended cues in a vigilance task. J Neurosci 1994; 14 (7): 4467-80
66. Rajkowski J, Kubiak P, Aston-Jones. Locus coeruleus activity in monkey: Phasic and tonic changes are associated with altered vigilance. Brain Res Bull 1994; 35 (5-6): 607-16
67. Prescott J, Jamieson D, Emdur N, et al. Acute effects of kava on measures of cognitive performance, physiological function and mood. Drug Alcohol Rev 1993; 12: 49-58
68. Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug Alcohol Rev 1997; 16: 147-55
69. Russell PN, Bakker D, Singh NN. The effects of kava on alerting and speed of access of information from long-term memory. Bull Psychonom Soc 1987: 25: 236-7
70. Münte TF, Heinze HJ, Matzke M, et al. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993; 27: 46-53
71. Heinze HJ, Münte TF, Matzke M, et al. Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials. Pharmacopsychiatry 1994; 27: 224-30
72. Singh NN, Singh SD. Kava: Clinical studies and therapeutic implications. In: Singh YN, editor. Kava, the Genus Piper. Amsterdam: Harwood Academic Publishers. In press
73. Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders: A randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 1997; 30: 1-5
74. Malsch U, Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology 2001; 157: 277-83
75. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd Ed. Washington, DC: American Psychiatric Association, 1987
76. Möller HJ, Heuberger ML. Anxiolytische potenz von D,L- kavain. Munch Med Wochenschr 1989; 131: 656-9
77. Lehmann E, Klieser E, Klimke A. et al. The efficacy of cavain in patients suffering from anxiety. Pharmacopsychiatry 1989; 22: 258-62
78. Lindenberg D, Pitule-Schödel H. D,L-kavain im vergleich zu oxazepam bei angstzustanden. Fortschr Med 1990; 108: 49-54
79. Woelk H, Kapoula O, Lehri S, et al. Behandlung von angst-patienten. Doppelblindstudie: Kava-spezialextrakt WS 1490 versus benzodiazepine. Z Allg Med 1993; 69: 271-7
80. Scherer J. Kava-kava extract in anxiety disorders: An outpatient observational study. Adv Ther 1998; 15: 261-9
81. Neto JT. Tolerability of kava-kava extract WS 1490 on anxiety disorders: Multicenter Brazilian study. Rev Bras Med 1999; 56: 280-4
82. Boerner RJ. Kava kava in the treatment of generalized anxiety disorder, simple phobia and specific social phobia. Phytother Res 2001; 15: 646-7
83. Watkins LL, Connor KM, Davidson JR. Effect of kava extract on vagal cardiac control in generalized anxiety disorder: Preliminary findings. J Psychopharmacol 2001; 15 (4): 283-6
84. Wheatley D. Kava-kava (L1150) in the treatment of generalized anxiety disorder. Prim Care Psychiatry 2001; 7 (3): 97-100
85. De Leo V, La Marca A, Morgante G, et al. Evaluation of combining kava extract with hormone replacement therapy in the treatment of postmenopausal anxiety. Maturitas 2001 Aug; 39 (2): 185-8
86. Bhate H, Gerster G, Gracza E. Orale pramedikation mit zubereitungen aus Piper methysticum bei operativen eingriffen in epiduralanasthesie. Erfahrungsheilkunde 1989; 6: 39-45
87. Staedt U, Holm E, Heep J, et al. Zum wirkungsprofil von D,Lkavain: Psychometrie, EEG und fremdbeurteilungsskala. Med Welt 1991; 42: 881-91
88. Neuhaus W, Ghaemi Y, Schmidt T, et al. Treatment of perioperative anxiety in suspected breast carcinoma with a phytogenic tranquilizer. Zentralbl Gynakol 2000; 11: 561-5
89. Scholing WE, Clausen HD. Über die wirkung von D,L-kavain: Erfahrungen mit dem Präparat Neuronika®. Med Klin 1997; 72: 1301-6
90. Geßner B, Cnota P. Untersuchung der vigilanz nach applikation von kava-kava-extrakt, diazepam oder plazebo. Z Phytother 1994; 15: 30-7
91. Frater AS. Medical aspects of yaqona. Fiji Med J 1976; 4: 526-30
92. Pfeiffer CC, Murphree HB, Goldstein L. Effect of kava in normal subjects and patients. In: Efron DH, Holmstedt B, Kline N, editors. Ethnopharmacologic Search for Psychoactive Drugs. New York: Raven Press, 1979: 155-61
93. Cawte J. Psychoactive substances of the South Seas: Betel, kava and pituri. Aust N Z J Psychiatry 1985; 19: 83-7
94. Gajdusek DC. Recent observations on the use of kava in the New Hebrides. In: Efron DH, Holmstedt B, Kline N, editors. Ethnopharmacologic Search for Psychoactive Drugs. New York: Raven Press, 1979: 119-25
95. Mathews JD, Riley MD, Fejo L, et al. Effects of the heavy usage of kava on physical health: Summary of a pilot study in an aboriginal community. Med J Aust 1988; 148: 548-55
96. Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol 1994; 3: 89-97
97. Gifford EW. Tongan myths and tales. Bishop Museum Bull 1924; 8: 71-2
98. Prescott J, McCall G, editors. Kava: Use and Abuse in Australia and the South Pacific. Kensington: National Drug and Alcohol Research Center, University of New South Wales, 1988
99. Davidson C. Hawaiian medicine. Med Age 1989; 25: 373-81
100. Süss R, Lehmann P. Hematogenous allergic contact dermatitis from kava, an herbal product. Hautarzt 1996; 47: 459-61
101. Shulgin AT. The narcotic pepper: The chemistry and pharmacology of Piper methysticum and related species. Bull Narc, 1973; 25: 59-74
102. Siegel RK. Herbal intoxication. JAMA 1976; 236: 473-6
103. Ruze P. Kava-induced dermopathy: A niacin deficiency? Lancet 1990; 335: 1442-597
104. Schelosky L, Raffauf C, Jendroska K, et al. Kava and dopamine antagonism [letter]. J Neurol Neurosurg Psychiatry 1995; 58 (5): 639-40
105. Volz HP. The anxiolytic efficacy of the kava special extract WS 1490 using long-term therapy: A randomized, double-blind study. Quart Rev Nat Med 1996; Fall: 185-6
106. Herberg KW. Zum einfluss von kava-spezialextrakt WS 1490 in kombination mit ethylalkohol auf sicherheitsrelevante leistungsparameter. Blutalkohol 1993; 30: 96-105
107. Almeida JC, Grimsley EW. Coma from the health food store: Interaction between kava and alprazolam [letter]. Ann Intern Med 1996; 125: 940-1
108. Hagemann U. Pharmaceutical products containing kava-kava (Piper methysticum) and kavain, including homeopathic preparations with a final concentration up to D6 [letter]. Newsletter of the German Federal Institute for Drugs and Medical Devices (BfArM). Berlin: German Federal Institute for Drugs and Medical Devices (BfArM), 2001 Nov 8
109. Waller DP. Report on Kava and Liver Damage. Silver Springs (MD): American Herbal Products Association, 2002
110. Strahl S, Ehret V, Dahm HH, et al. Necrotizing hepatitis after taking herbal remedies. Dtsch Med Wochenschr 1998: 123 (47): 1410-4
111. Sass M, Schnabel S, Kröger J, et al. Akutes leberversgen durch kava-kava: Eine seltene indikation zur lebertransplantation [abstract]. Z Gastroenterol 2001; 39: 491(P29)
112. Escher M, Desmeules J, Giostra E, et al. Hepatitis associated with kava, a herbal remedy for anxiety. BMJ 2001; 322: 139
113. Brauer RB, Pfab R, Becker K, et al. Fulminantes leberversagen nach einnahme des pflanzlichen heilmittels kava-kava [abstract]. Z Gastroenterol 2001; 39: 491(P30)
114. Kraft M, Spahn TW, Menzel J, et al. Fulminantes leberversagen nach einnahme des pflanzlichen antidepressivums kava-kava. Dtsch Med Wochenschr 2001; 126: 970-2
115. Schmidt J. Analysis of Kava Side Effects Reports Concerning the Liver [Online]. Lindenmaier M, Brinckmann J, translators. Available from URL: http://www.emersonecologics.com/ EmersonUpdate/EmersonUpdate-Vo10-Kava%20Report-M isc2002.pdf [Accessed 2002 Aug 9]
116. Schulz J, Meng G, Siegers C-P. Safety assessment of kavalactone-containing herbal drugs in comparison to other psychotropics. Arch Pharmacol 2001; 364 (3): R22